Дисертації з теми "Stage II patients"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-16 дисертацій для дослідження на тему "Stage II patients".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте дисертації для різних дисциплін та оформлюйте правильно вашу бібліографію.
Tsikitis, Vassiliki, David Larson, Marianne Huebner, Christine Lohse, and Patricia Thompson. "Predictors of recurrence free survival for patients with stage II and III colon cancer." BioMed Central, 2014. http://hdl.handle.net/10150/610351.
Повний текст джерелаDobriansky, V. V. "Risk factors for recurrent hypoglycemia in patients with type II diabetes mellitus in the prehospital stage." Thesis, БДМУ, 2022. http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/19824.
Повний текст джерелаObayashi(Nishiuchi), Aya. "MicroRNA-9-5p-CDX2 Axis: A Useful Prognostic Biomarker for Patients with Stage II/III Colorectal Cancer." Kyoto University, 2020. http://hdl.handle.net/2433/253179.
Повний текст джерелаBrand, Juanita M. "The lived experiences of six women during adjuvant chemotherapy for Stage I or II breast cancer." Virtual Press, 2005. http://liblink.bsu.edu/uhtbin/catkey/1317926.
Повний текст джерелаCaie, Peter David. "Discovery of novel prognostic tools to stratify high risk stage II colorectal cancer patients utilising digital pathology." Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/19527.
Повний текст джерелаHendrix, Ryan J. "Improved Survival after Administration of Neoadjuvant Chemotherapy in Patients with Clinical Stage I/II Pancreatic Ductal Adenocarcinoma." eScholarship@UMMS, 2019. https://escholarship.umassmed.edu/gsbs_diss/1029.
Повний текст джерелаMorris, Melinda. "Clinical and pathological predictors of survival for stage II and III colon cancer patients treated with or without chemotherapy : a population-based study." University of Western Australia. School of Surgery and Pathology, 2007. http://theses.library.uwa.edu.au/adt-WU2008.0012.
Повний текст джерелаSchrama, Jolanda Godefrida. "Patient selection for high-dose chemotherapy in stage II and IV breast cancer." [S.l. : Amsterdam : s.n.] ; Universiteit van Amsterdam [Host], 2004. http://dare.uva.nl/document/75451.
Повний текст джерелаMAIGNE, PHILIPPE. "Traitement de la maladie de hodgkin stade i-ii par radiotherapie exclusive : a propos de 67 patients du centre claudius regaud." Toulouse 3, 1993. http://www.theses.fr/1993TOU31057.
Повний текст джерелаPOURRAT, CHABROLET CORINNE. "Arteriopathie obliterante des membres inferieurs et hypertension arterielle : suivi longitudinal sur 10 ans d'une population de 125 patients du stade ii ; royat 1984-1993." Clermont-Ferrand 1, 1994. http://www.theses.fr/1994CLF1M026.
Повний текст джерелаHamy, Anne-Sophie. "Identification of Factors Predicting Sensitivity or Resistance to Neoadjuvant Chemotherapy in Breast Cancer Neoadjuvant treatment : the future of patients with breast cancer Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an “option” but an ethical obligation Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status BIRC5 (survivin) : a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort The presence of an in situ component on pre-treatment biopsy is not associated with response to neoadjuvant chemotherapy for breast cancer Chemosensitivity, tumor infiltrating lymphocytes (TILs), and survival of postpartum PABC patients treated by neoadjuvant chemotherapy Lymphovascular invasion after neoadjuvant chemotherapy is strongly associated with poor prognosis in breast carcinoma New insight for pharmacogenomics studies from the transcriptional analysis of two large-scale cancer cell line panels Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer Interaction between molecular subtypes, stromal immune infiltration before and after treatment in breast cancer patients treated with neoadjuvant chemotherapy COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial Comedications influence immune infiltration and pathological response to neoadjuvant chemotherapy in breast cancer." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS129.
Повний текст джерелаNeoadjuvant chemotherapy (NAC i.e. chemotherapy before surgery) is increasingly being used for aggressive or locally advanced breast cancer (BCs). Beyond clinical benefits, it represents an opportunity to monitor in vivo sensitivity to treatment. Based on the analysis of datasets of BCs patients treated with NAC, we aimed at identifying mechanisms associated with resistance or sensitivity to treatment.In the first part, we evaluated biological, clinical, pathological and transcriptomic patterns. We demonstrated that unexplored pathological features such as post-NAC lymphovascular invasion may carried an important prognostic information.In a second part, we analyzed impact of imune infiltration in BC and we described extensively the changes of tumor infiltrating lymphocytes (TILs) between pre and post-NAC samples. We showed that the prognostic impact of TILs was different before and after NAC, and was opposite in TNBC and HER2-positive BCs. Finally, we investigated the impact of comedications use during NAC. We found both positive effects - while enhancing immune infiltration and response to treatment - and negative effects with deleterisous oncologic outcomes in specific patients subgroups. In conclusion, the neoadjuvant setting represents a platform to both generate and potentially validate research hypotheses aiming at increasing the efficacy of treatment. The public release of real-life datasets of BC patients treated with NAC would represent a major resource to accelerate BC research
松本, 高明, та T. Matsumoto. "Postoperative DAV-IFN-β therapy does not improve survival rates of stage II and stage III melanoma patients significantly". Thesis, 2013. http://hdl.handle.net/2237/18452.
Повний текст джерелаLima, Isac da S. F. "Effects of Timing of Adjuvant Treatment on Survival of Patients with Stage III Colon Cancer and Stage II/III Rectal Cancer in Alberta." Master's thesis, 2010. http://hdl.handle.net/10048/1341.
Повний текст джерелаEpidemiology
Huang, Ming Ming. "Effects of Post-operative Adjuvant Chemotherapy and Radiotherapy on Serum Copper and Zinc Status in Stage II Breast Cancer Patients." 2004. http://www.cetd.com.tw/ec/thesisdetail.aspx?etdun=U0007-1704200714553714.
Повний текст джерелаMing, Huang Ming, and 黃明明. "Effects of Post-operative Adjuvant Chemotherapy and Radiotherapy on Serum Copper and Zinc Status in Stage II Breast Cancer Patients." Thesis, 2004. http://ndltd.ncl.edu.tw/handle/06969937429915668897.
Повний текст джерела臺北醫學大學
保健營養學系
92
Abstract In Taiwan, the incidence rate of female breast cancer has been increasing gradually every year, and has been the 4th leading cause of cancer death. This study was aimed to explore the effect of postoperative adjuvant chemotherapy (C/T) and radiotherapy (R/T) on serum copper, zinc, Cu/Zn ratio and RBC-SOD in female breast cancer patients. In the meantime, we analyzed the dietary intake and body weight change to understand whether the serum trace elements status of the patients were influenced by diet, C/T, or R/T. Results obtained from this study may provide some information for adequate nutrition support in clinical practice in the future. The results showed that serum copper, zinc, Cu/Zn ratio and RBC-SOD were not significantly different before and after C/T and R/T treatment in patients. During postoperative treatment, Cu/Zn ratio did not show significant difference, but a significantly positive correlation trend between several measurement was noted. Dietary zinc and protein intake did not significantly correlated with serum copper and zinc status. Calorie intake increased 300-100 Kcal/d and body weight showed an elevated trend with 3% increase after the postoperative treatment started, however, there were no obvious changes than before. The percentage of macronutrients intake were in normal ranges. Protein intake increased from 1.17 g/ kg BW to 1.39 g/kg BW when postoperative treatment began, and zinc intake was higher during treatment period, but showed no significant difference. The level of zinc intake was below RDNA before and after treatment. In conclusion, postoperative adjuvant chemotherapy and radiotherapy did not affect serum copper , zinc, Cu/Zn ratio and RBC-SOD in stage II breast cancer patients who take balance diet containing adequate amount of copper and zinc. Keywords: breast cancer, chemotherapy, radiotherapy, Cu, Zn, SOD
Chiang, Fu-Fan, and 蔣馥帆. "The Application of Data Mining Techniques to the Prognosis of Stage II Colorectal Cancer Patient." Thesis, 2014. http://ndltd.ncl.edu.tw/handle/5783bz.
Повний текст джерела國立中正大學
資訊管理學系暨研究所
102
According to the annual cancer registration report by the Health Promotion Administrative, Ministry of Health and Welfare in 2010, the deaths of Colorectal Cancer Malignancies was 11.39% of all malignancies. The ranking of the death rate was the third, and the number of cases was the first among the malignancies in Taiwan. Based on the statistics by a medical center in Taiwan, the cancer registration data base from 2007 to 2009, the patients in the stage II of Colorectal Cancer ranked the highest percentage ; the stage III was the second, and the stage IV was the third. This study collected the data of 283 patients from January 2003 to December 2009 in a medical center in Taiwan and applies the Decision Tree (DT), the Logistic Regression, and the Artificial Neural Networks (ANNs) to construct the survival prediction model of the Colorectal Cancer. The current study found that the constructed model of the Data Mining was the most appropriate by utilizing the ANNs. The accuracy was 74.56% (the ROC curve was 83%). The accuracy of the Decision Tree ranked second which was 73.14% (the ROC curve was 72%). The last one was the Logistic Regression and the accuracy was 71.73% (the ROC curve was 75%). According to these three models, eventually the survival of the patients in the stage II of the Colorectal Cancer can be predicted. These three models provide the survival prediction for the patients in the stage II of the Colorectal Cancer and provide suggestions and references for doctors to conduct treatment and evaluation.